Microviable Therapeutics

microviable.com ↗ ·Gijón ·Seed

Microviable Therapeutics is a Spanish preclinical-stage biotech spun out of the IPLA institute of the Spanish National Research Council (CSIC) in Gijón, Asturias, developing biological drugs derived from the human gut microbiota. Its PharmaBiota platform produces both complete microbiota ecosystem products (lead candidate MVT-201, aimed at multidrug-resistant infection) and defined bacterial consortia for oncology, infectious disease and dermatology, and it also commercialises the GutAlive anaerobic microbiome sampling kit sold in ~15 countries. It raised €1.5M in seed funding in April 2022 led by the private medical group Inmunomet and celebrated its 10th anniversary in 2026.

Founded

2016

Founders

Total funds raised

€1.5M

SectorsBiotech, Microbiome, Therapeutics, Healthtech & Bio, Medical Devices Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Abelardo Margolles Barros

Co-founder & Scientific Advisor (Research Professor, IPLA-CSIC)

Borja Sánchez

Co-founder & Scientific Advisor (Principal Investigator, IPLA-CSIC)

Claudio Hidalgo Cantabrana

CEO & Co-founder

Noelia Martínez Álvarez

R&D Director & Co-founder

Rafael M. Permuy

Chief Business Officer & Co-founder

Susana Delgado

Co-founder & Scientific Advisor (Principal Investigator, IPLA-CSIC)

Global models 5

Vedanta Biosciences

United States · www.vedantabio.com ↗

Develops defined bacterial consortia drugs from the human gut microbiome for infection (C. difficile, multidrug-resistant organisms) and immune disease, mirroring Microviable's consortia programmes.

$470MComparable

Finch Therapeutics

United States · www.finchtherapeutics.com ↗

Built complete-microbiome drug candidates (CP101) for recurrent C. difficile, the same full-ecosystem approach as Microviable's MVT-201.

$200MComparable

MaaT Pharma

France · www.maatpharma.com ↗

Makes pooled full-ecosystem microbiome drugs for oncology and infection-related complications, the closest European match to Microviable's PharmaBiota platform.

$150MComparable

Seres Therapeutics

United States · www.serestherapeutics.com ↗

Turns donor-derived and defined gut bacterial communities into licensed drugs (VOWST) against recurrent infection and antimicrobial-resistant pathogens.

$130MComparable

Microbiotica

United Kingdom · microbiotica.com ↗

Spun out of academic research (Sanger Institute) to develop defined gut bacterial consortia for immuno-oncology and ulcerative colitis, like Microviable's CSIC-born consortia pipeline.

$80MComparable